Established in 1943 as one of the national largest manufacturing and exporting bases in the chemical synthetic pharmaceuticals field, Shandong Xinhua Pharmaceutical Company Limited ("Shandong Xinhua") is in an leading position in the manufacturing technology and capacity for antipyretics and analgesics in China and is an important manufacturer in China for the drugs for central nervous system, steroids, cardio cerebrovascular system as well as finished dosage forms and pharmaceutical intermediates. With implementing the global market development strategy and adopting the international advanced standards in quality management, Shandong Xinhua has been granted the certifications of GMP, ISO9001, ISO14001, ISO 10012, and ISO22000. The main products of Shandong Xinhua have been granted the COS Certificate from EDQM and passed the site inspection from USA FDA. By taking the advantages of its solid scientific research strength, well-established quality system, high market reputation as well as being a listing company of H shares and A shares with sound capital structure and product portfolio. "XINHUA" brand was honored with the title of "Chinese Famous Brand" in China. With the high commitment to the product quality and development of the international markets, the Company has established the strategic partnership with dozens of MNCs, the products of the Company has been distributed to more than 60 countries and regions.
- Oct.9 - Oct.11 2018: Welcome to visit us at H7C71, CPhI Madrid [09-20]
- Jun.20-22 2018: Please visit us at W1B22, CPhI Shanghai [03-05]
- Apr.24-26 2018: Please visit us at BOOTH No.657, CPhI Philadelphia [03-05]
- Apr.11, 2017: Carbidopa granted COS/CEP [03-05]
- Nov., 2016: UK MHRA inspected plant No. 206(Finished dosages): ZERO critical & ZERO major deficiency [03-05]